$19.37
2.52%
Nasdaq, Nov 17, 04:00 pm EST. Closed.
ISIN
US24661P5008
Symbol
DCTH

Delcath Systems Inc Stock price

$19.37
+5.00 34.79% 1M
+8.28 74.66% 6M
+9.27 91.78% YTD
+10.76 124.97% 1Y
+16.92 690.61% 3Y
+9.38 93.89% 5Y
-265,824,980.63 100.00% 10Y
-102,547,199,980.63 100.00% 20Y
Nasdaq, Closing price Tue, Nov 17 2026
-0.50 2.52%

Is Delcath Systems Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$673.8m
Enterprise Value
$577.9m
Net debt
positive
Cash
$95.9m
Shares outstanding
34.6m
Valuation
P/E
1,937.0
P/S | estimate
7.1 | 5.8
EV/Sales | estimate
6.1 | 5.0
EV/FCF | ex SBC
33.0 | negative
P/B
5.6
Financial Health
Equity Ratio
90.0%
Return on Equity
2.4%
ROCE
-1.5%
ROIC
-2.0%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$20.2m | 21.2%
SBC as % of FCF
115.5%
SBC Growth 1Y
13.4%
Share Count Growth 1Y
-0.9%
Shareholder Yield
0.9%
Financials
Revenue | estimate
$95.4m | $115.8m
EBITDA
$-1.5m
EBIT
$-1.8m
Net Income
$530.0k
Free Cash Flow | ex SBC
$17.5m | $-2.7m
Growth
Revenue | estimate
35.9% | 35.9%
EBITDA
-128.2%
EBIT
-136.2%
Net Income
-76.2%
Free Cash Flow
352.5%
Margin
Gross
87.1%
EBITDA
-1.5%
EBIT
-1.9%
Net
0.6%
Free Cash Flow | ex SBC
18.4% | -2.9%
More
EPS
$0.0
FCF per Share
$0.5
Short interest
5.6%
Employees
156
Rev per Employee
$550.0k

Delcath Systems Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Delcath Systems Inc forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Delcath Systems Inc forecast:

Buy
92%
Hold
8%

Delcath Systems Inc Events

Past Events
NOV
9
Q3 2026 Earnings Call
9 days ago
AUG
6
Q2 2026 Earnings Call
3 months ago
MAY
7
Q1 2026 Earnings Call
6 months ago
FEB
26
Q4 2025 Earnings Call
9 months ago
NOV
4
Q3 2025 Earnings Call
about one year ago
OCT
20
Special Call - Delcath Systems, Inc.
about one year ago

Financial data from Delcath Systems Inc

Jun '26
+/-
%
95 95
36% 36%
100%
- Direct Costs 12 12
24% 24%
13%
83 83
38% 38%
87%
- Selling and Administrative Expenses 47 47
29% 29%
50%
- Research and Development Expense 38 38
101% 101%
39%
-1.46 -1.46
128% 128%
-2%
- Depreciation and Amortization 0.36 0.36
112% 112%
0%
EBIT (Operating Income) EBIT -1.81 -1.81
136% 136%
-2%
Net Profit 0.53 0.53
76% 76%
1%

In millions USD.

Don't miss a Thing! We will send you all news about Delcath Systems Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Delcath Systems Inc Stock News

Neutral
Business Wire
●
about 8 hours ago
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to three individuals whose grant date was in either ...
Neutral
Business Wire
●
6 days ago
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the Company will be featured on Health Uncensored with Dr. Drew in a segment titled “Precision Oncology: Changing the Game for Metastatic Liver Cancer.” The segment is scheduled to air nationally on Sun...
More Delcath Systems Inc News

Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's lead product candidate is the melphalan hydrochloride for injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its Phase III clinical trial products include FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial for intrahepatic cholangiocarcinoma. The company also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.

Head office United States
CEO Mr. Michel
Employees 156
Founded 1988
Website delcath.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today